Bone Biologics Corp
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
BBLG$0.33-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, 2024 | Year Ended December 31, 2023 | |
|---|---|---|
| Revenues · $ · - · $ · - | ||
| Operating expenses | ||
| Research and development | 2,130,385 | 6,907,824 |
| General and administrative | 2,088,776 | 2,520,479 |
| Total operating expenses | 4,219,161 | 9,428,303 |
| Loss from operations | (4,219,161) | (9,428,303) |
| Other income | ||
| Change in fair value of warrant liability | 51,081 | 892,693 |
| Interest income | 55,660 | 1,868 |
| Legal settlement, net of insurance | - | (414,989) |
| Total other income | 106,741 | 479,572 |
| Net loss | (4,112,420) | (8,948,731) |
| Deemed dividend on warrant inducements | (3,212,504) | - |
| Net loss attributable to common stockholders | $(7,324,924) | $(8,948,731) |
| Weighted average shares of common outstanding – basic and diluted | 1,517,235 | 263,137 |
| Loss per share – attributable to common stockholders, basic and diluted | $(4.83) | $(34.01) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.